Kiji Therapeutic, Incorporated in France and Spain in 2023, develops transformative off-the-shelf engineered cell therapies for life-threatening diseases. Kiji-TX has a platform to gene engineer iPSC derived MSC cells for a targeted and optimized therapeutic benefit. The first asset is engineered with IL10/CXCR4 and targets several autoimmune diseases.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 4, Rue Thénard, Paris,île-De-France 75005,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.kiji-tx.com
- Keywords
- 🔹 Small Molecules.
- HQ
- Paris, Île-de-France
Kiji Therapeutics Questions
Kiji Therapeutics's website is http://www.kiji-tx.com
Kiji Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/kiji-therapeutics
Kiji Therapeutics has
5 employees.
View email and phone details for 5
employees at Kiji Therapeutics.
Kiji Therapeutics's industry is
Biotechnology Research
Kiji Therapeutics's top competitors are
Agio Capital,
Adbio Partners,
Citius Pharmaceuticals, Inc.,
Lanova Medicines,
Oncoc4, Inc.,
Isct, International Society For Cell & Gene Therapy,
Surbio+,
Cynata Therapeutics,
Swarm Oncology,
Poseida Therapeutics, Inc..
Kiji Therapeutics's categories are Biotechnology Research
Kiji Therapeutics's founding year is 2023
